Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
11/5/2019
1
©2018 MFMER | slide-1
Chronic Diarrhea and Getting Over Fecal Incontinence
Amy Foxx-Orenstein, DO, MACG, FACPProfessor of MedicineDivision of Gastroenterology and HepatologyMayo Clinic
AOMA 39th Annual Fall Seminar
©2018 MFMER | slide-2
Disclosures
• None
11/5/2019
2
©2018 MFMER | slide-3
IBS-D Outline
• Evidence-based criteria to diagnose IBS
• Cost-effective evaluation
• Brief review of traditional and newer treatments for patients with IBS-D
©2018 MFMER | slide-4
Representative Case
• 35 year old female with 8 years of diarrhea, abdominal cramping and bloating on most days. No bloody stools or nocturnal episodes. Has 3-4 loose stools daily with urgency, never had an ‘accident’. LLQ cramping is relieved with movements. Has hypothyroidism and anxiety, on treatment. Weight is stable. No family history of IBD or colon cancer/polyps.
• Does she have IBS?• Are there other diagnosis to consider?• What tests would you do to evaluate cause?
11/5/2019
3
©2018 MFMER | slide-5
Recurrent abdominal pain, on average, ≥1 day per week in the last 3 months, associated with ≥ 2 of the following:
• Related to defecation
• Change in frequency of stool
• Change in form (appearance) of stool
Rome IV Criteria for IBS
Bristol Stool Form Scale
Criteria should be fulfilled for the last 3 months with
symptom onset ≥ 6 months before diagnosis
Lacy BE et al. Gastroenterology. 2016;150:1393-1407
IBS-D IBS-M
©2018 MFMER | slide-6
What Else Could It Be?Differential for diarrhea is broad and the history will divulge many clues
• Infectious
• Medication
• Bile acid
• Microscopic colitis
• Celiac
• Caffeine
• SIBO
• IBD
• Disaccharidase deficiency
• Food related
• Toxins
• Villous adenoma
11/5/2019
4
©2018 MFMER | slide-7
Diagnostic Testing for IBS-D and IBS-M symptoms
IBS-DIBS-DIBS-D IBS-MIBS-MIBS-M
•CRP, fecal calprotectin
• IgA ttG ± quantitative IgA
•Colonoscopy with random biopsies and TI exam if appropriate
•Consider EGD with small bowel biopsies
•CRP, fecal calprotectin
• IgA ttG ± quantitative IgA
CRP = C-reactive proteinttg = tissue transglutaminase.
Chey WD, et al. JAMA. 2015;313:949
Limited testing
©2018 MFMER | slide-8
Prevalence of Structural Abnormalities in IBS Patients Compared with Controls
7.7
0.4 1.5
26.1
00
5
10
15
20
25
30
Microscopic colitis more common in patients aged
≥45 years
Pat
ient
s, %
IBS patients (n=466) Controls (n=451)
Adenomas IBD Microscopic colitis
N/A
Chey WD et al. Am J Gastroenterol. 2010;105:859
Limited testing
11/5/2019
5
©2018 MFMER | slide-9
• Onset of symptoms after age 50
• GI bleeding or iron-deficiency anemia
• Nocturnal diarrhea
• Unintended weight loss
• Family history of organic GI disease (colorectal cancer, IBD, celiac)
Alarm Features
Proceed with testing
©2018 MFMER | slide-10
Celiac is Common in IBS Patients with Diarrhea
Prevalence of biopsy-proven celiac disease in IBS-D vs controls
4.34 (1.78-10.58)
International meta-analysisFord et al. Archives Int Med. 2009;169:651
11/5/2019
6
©2018 MFMER | slide-11
Breath Testing in IBS
Carbohdrateload
Colonic fermentation
H2 and/or methane
• Tests for CHO maldigestion and SIBO
• Conditions associated with bloating
• Heterogeneity in test performance, preparation, indications, and interpretation of results
Rezaie A et al. Am J Gastroenterol. 2017;112(775
CHO = carbohydrateSIBO = small intestinal bacterial overgrowth
©2018 MFMER | slide-12
Food and IBS Symptoms
69 6458 54
0
20
40
60
80
100
Pat
ient
s, %
Small meals Avoiding fat Increasingfiber
Avoiding milk products
IBS Patients Reporting Symptom ImprovementWith Intervention
(N=1,242)
60% of patients report worsening of symptoms after meals
Simren M et al. Digestion. 2001;63:108Halpert et al. Am J Gastroenterol. 2007; 102:1972
11/5/2019
7
©2018 MFMER | slide-13
Food and IBS Symptoms: Restriction Diets
• FODMAPS are an important trigger of meal-related symptoms in IBS
• Gluten-free diet found to be beneficial in some patients with IBS-D
• Wheat contains fructans and other proteins that may also cause symptoms in IBS patients
• Food antigens may cause changes in the intestinal mucosa of IBS patients
Shepherd SJ et al. Am J Gastroenterol. 2013;108:707;Biesiekierski JR et al. Gastroenterology. 2011;106:508;Vazquez-Roque MI et al. Gastroenterology. 2013;144:903;Chey WD, et al. JAMA. 2015;313:949
©2018 MFMER | slide-14
Low FODMAP vs mNICE Diet:Adequate Relief
41
52
0
10
20
30
40
50
60
Proportion of patients that answered “Yes” for ≥50% of weeks 3 and 4
N=45
mNICE Low FODMAP
N=38
Pat
ien
ts w
ith
A
deq
uat
e R
elie
f, %
P=0.3055
“In the last week, have you had adequate relief of your GI symptoms?”
mNICE, modified National Institute for Health and Care Excellence. Patients were instructed to eat small frequent meals, avoid trigger foods, and avoid excess alcohol and caffeine
Eswaran SL, et al. Am J Gastroenterol. 2016;111:1824-1832.
11/5/2019
8
©2018 MFMER | slide-15
mNICE vs FODMAPWeekly Pain and Bloating Scores
○
§§
§
1
2
3
4
5
6
Baseline Week 1 Week 2 Week 3 Week 4
Ave
rag
e D
aily
Ab
do
min
al P
ain
S
core
s (0
-10)
m-NICE Low FODMAP
#
§§
§
1
2
3
4
5
6
Baseline Week 1 Week 2 Week 3 Week 4
Ave
rag
e D
aily
Ab
do
min
al
Blo
atin
g S
core
(0-
10)
m-NICE Low FODMAP
Abdominal Pain Scores Bloating Scores
mNICE, modified National Institute for Health and Care Excellence. Patients were instructed to eat small frequent meals, avoid trigger foods, and avoid excess alcohol and caffeine
Eswaran SL, et al. Am J Gastroenterol. 2016;111:1824-1832.
©2018 MFMER | slide-16
Overview of IBS-D Therapies: MOA*
• Modulation of gut flora• Antibiotics, Probiotics, gastric acidity, diet
• 5-HT3 antagonists• Alosetron
• Antidepressants/antianxiety agents• TCA’s, SSRI’s
• Opioid receptor modulators• Loperamide, diphenoxylate, Eluxadoline
• Antispasmodics/Peppermint Oil
• Bile acid binding agents• Colestid, Cholestyramine
*MOA = Mechanisms of action
11/5/2019
9
©2018 MFMER | slide-17
Loperamide and Antispasmodics for IBS
Loperamide
Antispasmodics Clinical trials
Patients treated
23
2,154
Clinical trials
Patients treated
2
42
Recommendation
Strong*
Quality of evidence
Very LowRecommendation
Weak
Quality of evidence
Low
Ford AC, et al. Am J Gastroenterol. 2014;109:S2-S26
*FOR DIARRHEA
©2018 MFMER | slide-18
Probiotics for IBS
Clinical trials Patients treatedRecommendation
WeakQuality of evidence
LowRecommendations regarding individual species, preparations, or strains cannot be made because of insufficient and conflicting data
23 2,575
Ford AC, et al. Am J Gastroenterol. 2014;109:S2-S26
11/5/2019
10
©2018 MFMER | slide-19
Alosetron for IBS-D
• Dose• .5-1 mg BID• Females• Not first line treatment
Alosetron is effective in
females with IBS-D
Recommendation
Strong
Quality of evidence
High
Ischemic colitis0.95 cases/1000 patient-years
Difficult constipation0.36 cases/1000 patient-years
Rare Adverse EffectsAssociated with Alosetron
Ford AC, et al. Am J Gastroenterol. 2014;109:S2-S26
©2018 MFMER | slide-20
Rifaximin for IBS-D
TARGET 1 TARGET 2 Combined
40.8 40.6 40.731.2 32.2 31.7
0
20
40
60
80
100
Pat
ient
s, %
P=0.01P=0.03 P<0.001
Adequate Relief of Global* IBS Symptoms
Rifaximin Placebo
3336.9
25 29.3
0
20
40
60
80
100
Pat
ient
s, %
First repeat treatment
Second repeat treatment
P=0.04P=0.02
First and Second Retreatments
Urgency, bloating, pain, stool consistency
Pimentel M, et al. N Engl J Med. 2011;364:22
11/5/2019
11
©2018 MFMER | slide-21
Rifaximin
• 550 mg TID 2 weeks
• Recurrence of symptoms can be retreated up to two times, same regimen
Schoenfeld P, et al. Aliment Pharmacol Ther. 2014;39:1161
©2018 MFMER | slide-22
Antidepressant Agents in IBS-D
• Meta-analysis 16 RCT TCA reduced global pain and IBS symptoms
• SSRI’s may increase intestinal transit
• SNRI’s have not been adequately studied
Antidepressant actions in IBS
Antidepressant action
Visceral analgesia
Changes in motility
Smooth muscle relaxation
Ford AC et al. Am J Gastroenterol. 2014;109:1350;Grover M, et al Gastroenterol Clin N Am. 2011;40:183;Chey WD, et al. Gut Liver. 2011;5:253;Gorard DA, et al. Aliment Pharmacol Ther. 1994;8:159
11/5/2019
12
©2018 MFMER | slide-23
Prescribing Antidepressants in IBS
Consider specific symptoms
TCA’s in IBS-D
SSRI for anxiety
Consider Side Effects
TCA’s → constipation
SSRI → diarrhea
Start LOW dose and titrate
8 weeks for full response
6-12 months treatment
Sobin WH et al. Am J Gastroenterol. 2017;112:693;Grover M et al. Gastroenterol Clin N Am. 2011;40:183;Dekel R et al. Expert Opin Invest Drugs. 2013;22:329
©2018 MFMER | slide-24
Eluxadoline for IBS-D
Placebo BID Eluxadoline 75 mg BID Eluxadoline 100 mg BID
0
20
40
60
80
100
0
20
40
60
80
100
P<0.001
Weeks 1–26Weeks 1–12
Res
po
nd
ers,
%
P<0.001
P<0.001
P<0.001
Reduced abdominal pain > 30% compared to baseline and stool consistency < 5/d daily, for >50% of days in trial
Lembo AJ, et al. N Engl J Med. 2016;374:242
Mixed opioid receptor agonist (mu) and antagonist (delta)
11/5/2019
13
©2018 MFMER | slide-25
Eluxadoline Adverse Events
Sphincter of Oddispasm events 0.6% (10 /1666) In patients who did not have gall bladders
PancreatitisAlcohol use and biliary sludge increase risk
AdverseEvents
Placebo (n=808)
Eluxadoline75 mg
(n=859)
Eluxadoline100 mg (n=807)
n (%)
Constipation* 20 (2.5) 60 (7.4) 74 (8.6)
Nausea 41 (5.1) 65 (8.1) 64 (7.5)
Abdominal pain† 33 (4.0) 47 (5.9) 62 (7.2)
Vomiting 11 (1.4) 32 (4.0) 36 (4.2)
Gastroenteritis‡ 27 (3.4) 36 (4.4) 19 (2.2)
URI 32 (4.0) 27 (3.3) 47 (5.5)
Nasopharyngitis 27 (3.3) 33 (4.1) 23 (2.7)
©2018 MFMER | slide-26
Prescribing Eluxadoline
• 100 mg BID with food
• 75 mg BID for patients with hepatic impairment
Contraindications
1. Bile duct disorders
2. NO Gallbladder
3. History of pancreatitis
4. Severe constipation or liver disease
5. ETOH daily
11/5/2019
14
©2018 MFMER | slide-27
Peppermint Oil for IBS
• Improved total IBS symptom score, frequency and intensity of symptoms over 4 weeks (p<0.02)
• Adverse events: dyspepsia
• Prescribing • 180 mg tid
0
20
40
60
80
100
AbdominalPain or
Discomfort
AbdominalBloating orDistension
Pain atEvacuation
Sym
pto
m r
edu
ctio
n, %
Placebo TID(n=37)
Peppermint oil 180 mg TID (n=35)
Cash BD, et al. Dig Dis Sci. 2016;61:560
©2018 MFMER | slide-28
Psychological Therapy is Effective in Many Patients With IBS
• 20 studies• Mindfulness, cognitive behavioral therapy, psychotherapy,
hypnosis
Psychological therapy
(%)
Control therapy
(%)RR symptoms remain
(95% CI)
49.1 27.5 0.67(0.57-0.79)
Ford AC et al. BMJ. 2008;337:a2313.Walter SA et al. Neurogastroenterol Motil 2013;25:741.Halland M, Talley NJ. Nat Rev Gastroenterol Hepatol 2013;10:13.
Patients often respond to psychological support, including strong physician-patient relationship
N=1278
11/5/2019
15
©2018 MFMER | slide-29
Exercise Has a Positive Impact on IBS Symptoms
• Randomized to physical activity* or maintain lifestyle
• Control group had significantly higher IBS symptom scores than patients in physical activity group
• Physical activity improvedIBS symptom scores (p=0.003)
Johannesson E et al. Am J Gastroenterol. 2011;106:915-922.
500
400
300
200
100
0
IBS
Sev
erit
y S
core
Control group Physical activity group
P = 0.001
Start 12 Weeks
*Intervention: 20-60 minutes moderate to vigorous exercise 3-5 times weekly
(N=75)
©2018 MFMER | slide-30
Summary IBS-D
• Diagnose using symptom-based criteria
• Check TTG, CRP• Consider referral for endoscopy, breath tests
• Educate• Primary role of diet in managing IBS
• Smaller meals, FODMAP, elimination • Medications to achieve a goal: reduce pain and
diarrhea, improve quality of life
• Psychological therapy
• Exercise
11/5/2019
16
©2018 MFMER | slide-31
The End
But there’s more…
©2018 MFMER | slide-32
Evaluation of Chronic Diarrhea (not IBS)
11/5/2019
17
©2018 MFMER | slide-33
Why is Chronic Diarrhea Important?
• Diarrhea is common• You will see it!• Affects 5% of the adult population
• $$ There can be considerable expense in the work-up/management.
• Cost effective evaluation
• Differential can be broad• Alarm features are key
©2018 MFMER | slide-34
Outline
• Stepwise approach to diagnosing and evaluating chronic diarrhea
• Features of chronic diarrhea that warrant increased attention
• What and when tests are warranted
11/5/2019
18
©2018 MFMER | slide-35
Representative Case
• 53 y/o woman with diarrhea for 2 years. She has 4-6 watery stools daily, no formed stool. No blood, but she has nocturnal stools, cramps and bloating. Medical history of hypothyroidism and depression (treated). Underwent a hysterectomy and radiation therapy for cervical cancer 5 years ago.
• Does she have IBS?• Are there historical clues in this case?• What testing would you do?
©2018 MFMER | slide-36
Step-Wise Approach to Chronic Diarrhea
• 1. Does the patient truly have diarrhea?
• 2. Is the diarrhea really chronic?
• 3. Can you categorize the diarrhea?
• 4. Are there historical clues to the diagnosis?
• 5. Is it diet or medication-induced?
• 6. Is there a factitious component?
Schiller LR, et al. CGH 2017;15:182
11/5/2019
19
©2018 MFMER | slide-37
Step 1: Does the patient truly have diarrhea?
• Fecal incontinence?
• Overflow from fecal impaction?
• Perception versus reality of volume / frequency?
©2018 MFMER | slide-38
Definition of diarrhea
• In past, based on volume and time:• >200-250 g liquid per day• >4 weeks
• Current way we diagnose:• >3 unformed BM/day• >25% loose or mushy stools• Bristol stool scale 6 or 7
11/5/2019
20
©2018 MFMER | slide-39
Step 2: Does the patient have acute or chronic diarrhea?
• Acute = up to 4 weeks
• Chronic = >4 weeks
OR
©2018 MFMER | slide-40
Step 3: Can you categorize the diarrhea?
• Large or small bowel intestine source• Often differs in volume and frequency
• Watery• Secretory versus osmotic
• Inflammatory• Bloody stools, abdominal pain, fever, tenesmus
• Fatty• greasy, oily, difficult to flush, floating stools, smelly
11/5/2019
21
©2018 MFMER | slide-41
Small bowel:large volume, vitamin andmineral deficiencies
Colon:Smaller volume (not always),frequent, bloody, tenesmuswith rectal involvement
©2018 MFMER | slide-42
Tests Based on Characteristics
• Watery: Secretory versus Osmotic• Osmotic gap = 290 mOsm/kg-2(stool Na+K)
• Gap < 50 Secretory• Gap > 100 Osmotic
• Stool osmolality:• Should be the same as serum
• Lower - urine or water contamination• Higher - stool collection sitting around
e.g. 2(140+ 4)= 288
11/5/2019
22
©2018 MFMER | slide-43
Osmotic Secretory
Daily volume <1L >1L
Effect of Fast Stops continues
Stool osmolality 290 290
Osmotic gap >100 <50
Common causes Malabsorption*PEG**, lactulose, Mg+ antacids, sorbitol/xylitol
Cholera, toxins,bile acid, VIPoma, gastrinoma, diabetic diarrhea, microscopic colitis, factitious, villous adenoma
*Malabsorption e.g . Fructose, lactose, bacterial overgrowth (SIBO)**PEG = polyethylene glycol
©2018 MFMER | slide-44
Osmotic Secretory
Testing Strategy
Dietary reviewMalabsorption tests (breath tests, avoidance, small bowel biopsy)Stool magnesium
CulturesStructural evaluation: colon biopsies.NeuroendocrineVIP, calcitonin, gastrin
11/5/2019
23
©2018 MFMER | slide-45
Tests based on characteristics
• Inflammatory:• +CRP, fecal calprotectin or lactoferrin
• If positive, these are nonspecific• Differential:
• infection, inflammation, ischemia, radiation
• Often structural evaluation is needed• colonoscopy and/or EGD with biopsies,
CT enterography, MR enterography
©2018 MFMER | slide-46
Tests based on characteristics
• Fatty / Steatorrhea• Symptoms: malodorous diarrhea, weight
loss, vitamin ADEK deficiencies• Etiology: pancreatic, mucosal (e.g celiac,
Whipple’s disease)• Tests:
• Qualitative fecal fat (Sudan stain) –’meh’!• Fecal elastase ( pancreatic disease)• Quantitative fecal fat (collection 24-72 hr)
normal < 7g/day or <14 if diarrhea
‘meh’ = low sensitivity/specificity
11/5/2019
24
©2018 MFMER | slide-47
Step 4: Are There Historical Clues to the Diagnosis?
• Abdominal pain/functional issues - IBS
• Autoimmune, iron deficiency, family history, itchy rash - celiac
• Female, culprit meds - microscopic colitis
• Bariatric surgery (RYGB), radiation, paralytic motility issues - SIBO
• Younger, bloody stool, fever, family history IBD, extra-intestinal features - IBD
©2018 MFMER | slide-48
Irritable bowel syndrome (IBS) ROME 4
• Recurrent abdominal pain on average at least 1 day/week in the last 3 months with 2 or more features:
• Related to defecation• Change in frequency of stool• Change in form/consistency of stool
• Symptoms present at least 6 months
• In absence of alarm features manage symptoms
Gastroenterology 2016:150:1393
11/5/2019
25
©2018 MFMER | slide-49
Important in History/Exam
• If ALARM features are present, further workup is needed:
• Bloody stool, weight loss, family history of IBD or bowel cancer, new onset, older age, immunosuppressed
©2018 MFMER | slide-50
Step 5: Does the Patient Have Diet-Induced Diarrhea?
• DIET• Caffeine• Soda, fruit/juice (fructose)• Sweeteners (sucrose)• Sugar free anything (xylitol)• Dairy (lactose)• Wheat (celiac, allergy, sensitivity)• Syrups, elixirs (sorbitol)
11/5/2019
26
©2018 MFMER | slide-51
Step 5: Does the Patient Have Medication-Induced Diarrhea?
• >700 drugs implicated
• Makes up 7% of medication side effects!
Some to Remember: NSAID
Metformin
Antibiotic
PPI
SSRIs
Mg+
Angiotensin receptor blockers (olmesatan)
Herbal products
Many chemotherapy agents
Rubio-Tapia A, et al. Mayo Clinic Proc 2012;87:732Prieux-Klotz C, et al. Target Oncol 2017;12:301
©2018 MFMER | slide-52
Step 6: Is there a factitious component?
• Stool osmolality not equal to 290 (diluted)• Munchausen syndrome
• Melanosis coli• Pigment from stimulant laxative use• Benign/reversible• Up to 15% undergoing diarrhea workup
11/5/2019
27
©2018 MFMER | slide-53
Evaluation May Include:
Stool Tests
Endoscopy
Imaging
Quantitative Stool Tests
Baseline Labs CBC, TTG, TSH, e-lytes,CRP, vitamin levels
Colonoscopy with TI exam and biopsy,EGD with SB biopsy
CT enterography, MRE
24-72 hour fat or bile acid collection
Infectious panel, parasites (Giardia),elastase, c diff, osm, Calprotectin
Very Individualized!
©2018 MFMER | slide-54
Summary
• Many causes of diarrhea can be deciphered from a careful history and examination
• A stepwise approach for diarrhea is cost-effective and efficient.
• #1. Does the patient truly have diarrhea?
• #2. Is it chronic?
• #3. How is it characterized (watery, fatty, inflammatory)
• #4. Historical clues to the diagnosis? (travel, illness, medications)
• #5. Diet or medication induced?
• #6. Could it be factitious?
11/5/2019
28
©2018 MFMER | slide-55
Seventh Inning Stretch!
©2018 MFMER | slide-56
Fecal Incontinence
11/5/2019
29
©2018 MFMER | slide-57
Objectives: you will be able to
•Understand types of FI and impact of the disorder
•Take a focused history
•Maximize conservative therapy
©2018 MFMER | slide-58
Fecal incontinence
• FI: involuntary loss of stool or liquid feces
• Anal incontinence: involuntary loss of gas• Prevalence: 18% in the community, 47%
in nursing home residents
Serious, Devastating disorder• Impairs quality of life, limits socialization,
predisposes to institutionalization, higher morbidity
• Patients rarely discuss symptoms• Often misdiagnosed as diarrhea
Gorina Y et al. NCHS Vital Health Stat 2014
11/5/2019
30
©2018 MFMER | slide-59
Types of incontinence
• Passive: involuntary discharge without awareness (loss of perception, or impaired rectoanal reflexes)
• Urge: discharge despite active attempts to contain (disruption of sphincter function and/or rectal capacity)
• Fecal seepage: After a movement; incomplete evacuation (Intact mechanisms of function)
©2018 MFMER | slide-60
Risk Factors of FI
• Diarrhea -
• Rectal urgency -
• Advancing age
• Increased body mass index
• Cholecystectomy
• Anal fistula
• Birth related trauma, multiparity
• Urinary incontinence
• Chronic illness (e.g. DM)
• *Overflow (constipation)
Independent risk factors
Average annual costs per person*treat constipation Salix.com
11/5/2019
31
©2018 MFMER | slide-61
Relative Frequencies of Common Mechanisms of FI
0% 20% 40% 60% 80% 100%
Anal spincter dysfunction
Pudendal neuropathy
Impaired rectal sensation
Poor rectal compliance
Other 5%
35%
50%
50%
80%
Frequency
©2018 MFMER | slide-62
Bristol Stool Form Scale
11/5/2019
32
©2018 MFMER | slide-63
Diagnosis: Take a focused history
• Ask directly about the presence of FI
• Identify conditions that predispose to FI
• Determine appearance using BSS*, frequency, volume, urgency
• Bowel diaries are superior to self reports
Strength of recommend-
ation
Quality of evidence
Strong High
Strong High
Strong Moderate
Strong Moderate
ACG Clinical Guidelines: Management of Benign Anorectal Disorders 2014
*Bristol Stool Scale
©2018 MFMER | slide-64
Recommendation for Physical Examination of FI
• Perform a physical examination to eliminate diseases to which FI is secondary.
• Visually inspect the anorectum.
• Perform digital exam before making a referral for anorectal manometry*.
Strength of recommend-
ation
Quality of evidence
Strong Moderate
Strong Moderate
Strong Moderate
*hard stool = overflow incontinence
ACG Clinical Guidelines: Management of Benign Anorectal Disorders 2014
11/5/2019
33
©2018 MFMER | slide-65
Recommendations for diagnostic testing of FI
• Anorectal manometry in patients who do not respond to conservative measures
• Image anal canal for patients with reduced anal pressures
Strength of recommend-
ation
Quality of evidence
Strong Moderate
Weak Moderate
ACG Clinical Guidelines: Management of Benign Anorectal Disorders 2014
©2018 MFMER | slide-66
Treatment
11/5/2019
34
©2018 MFMER | slide-67
Recommendations for conservative treatment of FI
• First-line management includes education, bulk stool, diet modification, skin care
• Prescribe anti-diarrheal agents
• Education is more effective and superior to pelvic floor exercises
Strength of recommend-
ation
Quality of evidence
Strong Moderate
Strong Low
Strong Moderate
ACG Clinical Guidelines: Management of Benign Anorectal Disorders 2014
©2018 MFMER | slide-68
Minimally invasive treatments• Injectable agents
• Radiofrequency ablation
• Barrier devices
• Neuromodulation • Sacral stimulation
11/5/2019
35
©2018 MFMER | slide-69
Recommendations for minimally invasive procedures for FI by GI’s
• Injectable bulking agents
FDA-A 2012
Office procedure
Minimally invasive
• SECCA (radiofrequency ablation)
Strength of recommend-
ation
Quality of evidence
Moderate Moderate
Weak Insufficientevidence
ACG Clinical Guidelines: Management of Benign Anorectal Disorders 2014
©2018 MFMER | slide-70
Anal Plugs
Lukacz E, Wexner S. Dis Col Rec 2015;58:892-898
Renew Insert device
soft silicone
11/5/2019
36
©2018 MFMER | slide-71
Plugs…
Coloplast Peristeen Anal Plug
Absorbent foam, cup-shaped device.Covered by a dissolvable filmStay in place for 12 hours
©2018 MFMER | slide-72
Vaginal Plugs..
Pelvalon Eclipse Vaginal insert
11/5/2019
37
©2018 MFMER | slide-73
More Plugs……. NO
©2018 MFMER | slide-74
Sacral Nerve Stimulation: Interstim® • 96% had a greater than 50% improvement in
their ability to defer defecation
• Change battery every 5 years
• Concluded• Improvement in symptoms for up to 10 years
in majority of patients. Some patients will experience deterioration in their symptoms over time.
First line treatment after conservative care
A George, et al. GUT 2011
11/5/2019
38
©2018 MFMER | slide-75
FI surgical treatment
• Sacral nerve stimulation
• Anal sphincteroplasty for severe sphincter defect
• Graciloplasty and artificial sphincter
• Colostomy
Strength of recommend-
ation
Quality of evidence
Strong Moderate
Weak Low quality evidence
Weak Insufficientevidence
Strong Moderate
ACG Clinical Guidelines: Management of Benign Anorectal Disorders 2014
©2018 MFMER | slide-76
External protection
11/5/2019
39
©2018 MFMER | slide-77
For Patients: Management Tips
1. Avoid trigger foods and caffeine
2. Bristol Stool Scale #4
3. Anti-diarrheal AFTER movement
4. Enema prior to activity
5. Have a change of clothes
6. Blot more, wipe less
©2018 MFMER | slide-78
Thank you!